PDF   Print   View All
January 22, 2003
REBROADCAST OF HEMISPHERX'S JANUARY 21, 2003 CONFERENCE CALL AVAILABLE ON COMPANY'S WEBSITE OR VIA TELEPHONE REPLAY
Philadelphia, PA, Wednesday, January 22, 2003: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that an audio replay of the Company’s conference call on Tuesday, January 21, 2003 at 11:00 AM EST is available on the Company’s website, www.Hemispherx.net, or via telephone from January 22, 2002 through Friday, February 7, 2003.

During the call Dr William Carter, President and CEO of Hemispherx, focused his presentation on the company’s strategy and events surrounding the expansion of Hemispherx’s clinical trails, strategic partner support regarding the funding of this expansion and the recent registration of shares. Dr. Carter also discussed how these events relate to the overall commercialization process for it’s product pipeline.

In order to listen to the rebroadcast, please go to www.Hemispherx.net and follow the link, or dial (800) 428 – 6051 or (973) 709 – 2089 for the telephone replay and state the password, which is 283031.

ABOUT HEMISPHERX

Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, you can visit the corporate website at www.hemispherx.net.


Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554

Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Wesley Stanton, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746

Media:
Rubenstein Associates, Inc.
Robin Wagge (212) 843-8006


HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.